Almatica is Alvogen's branded medicines arm in the US, with a pipeline primarily focused on CNS products.  Gralise® is the company's lead marketed product, a once-daily form of gabapentin used to treat postherpetic neuralgia (PHN), pain related to shingles. The company also has a pipeline of developmental CNS therapies, with the lead product expected to launch in late 2021.  The company expects to leverage its internal development and manufacturing capabilities to launch at least five products in the next three years.

Almatica is also actively pursuing the expansion of its US product portfolio through the in-licensing and acquisition of products that are either marketed or in late stage development. The growth of the company's business is supported by a broad range of in-house R&D, manufacturing and commercial capabilities.

Almatica Pharma LLC, a subsidiary of Alvogen, is a privately held, US pharmaceutical company focused on the development, acquisition and commercialization of brand-named pharmaceutical products. Its current product portfolio covers a wide range of therapeutic areas including psychiatry, pain management, anti-infectives and cardiovascular disorders. 